A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

Ebola Clinical Trial

Official title:
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, Reactogenicity, and Consistency of a Heterologous 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN®-Filo in Adult Participants

Status Completed

Clinical Trial Summary

The purpose of this study is to demonstrate that the paired 2-dose vaccine regimens from 3 consecutively manufactured lots of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 and 3 consecutively manufactured lots of Modified Vaccinia Ankara Bavarian Nordic vector encoding multiple filovirus proteins (MVA-BN-Filo) including the ebola virus mayinga glycoprotein as Dose 2, administered at a 56-day interval, induce an equivalent humoral immune response.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Ebola

Clinical Trial Details

NCT number	NCT04228783
Study type	Interventional
Source	Janssen Vaccines & Prevention B.V.
Contact
Status	Completed
Phase	Phase 3
Start date	February 18, 2020
Completion date	April 25, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05284097` - Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study	Phase 2
Completed	`NCT02240875` - A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo	Phase 1
Completed	`NCT05064956` - Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)	Phase 2
Completed	`NCT05079750` - A Study of a New Vaccine Against Two Types of Ebola	Phase 1
Completed	`NCT04385719` - Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy	Phase 2
Active, not recruiting	`NCT05301504` - A Study in Tanzania of a New Vaccine Against Two Types of Ebola	Phase 1
Completed	`NCT00646152` - Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study	Phase 1
Completed	`NCT02818582` - GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen	Phase 2
Completed	`NCT02370589` - Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects	Phase 1
Active, not recruiting	`NCT03031912` - African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola	Phase 2